Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma

In this article (Mol Cancer Res 2015;13:775–83), which appeared in the April 2015 issue of Molecular Cancer Research (1), the grant support section was missing a funding source. The corrected grant support section is below. The authors regret the error.

This work was supported by the Lombardy Region (ID14546A) and the Italian Association for Cancer Research (AIRC 2013 IG-14249).